
PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW124408 |
UDP-N-acetyl-D-GlucosaminePseudomonas aeruginosa
|
Creator: Marlon Yesid Cáceres Ortiz Created On: January 01, 2021 at 10:21 Last Updated: January 01, 2021 at 10:21 |
PW244655 |
Uliana1Saccharomyces cerevisiae
|
Creator: Guest: Anonymous Created On: May 07, 2024 at 03:49 Last Updated: May 07, 2024 at 03:49 |
PW145857 |
drug action
Ulipristal Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:50 Last Updated: October 07, 2023 at 16:50 |
PW176158 |
Ulipristal Predicted Metabolism Pathway newHomo sapiens
Metabolites of Ulipristal are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:23 Last Updated: November 29, 2023 at 14:23 |
PW127826 |
drug action
Ulobetasol Action PathwayHomo sapiens
Ulobetasol, also known as Halobetasol, is a highly potent corticosteroid used to treat corticosteroid-responsive dermatoses. This drug is available as a topical cream, foam, spray, or ointment. Ulobetasol is a glucocorticoid receptor agonist and is structurally related to clobetasol. By binding to the glucocorticoid receptor, it influences transcription factors AP-1 and NF-kB to block the transcription of COX-2/prostaglandin G/H synthase 2 which reduces the amount of prostanoids being produced from arachidonic acid. Prostanoids such as PGI2 and thromboxane A2 influence the effects of inflammation through vasoconstriction/dilation, pain sensitivity, and platelet aggregation. This drug also affects the promoter of annexin-1, an important inflammatory protein as it affects leukocytes and blocks phospholipase A2 which reduces the amount of arachidonic acid being cleaved from the phospholipid bilayer. Reducing the amount of arachidonic acid formed further decreases the concentrations of prostanoids mentioned calming inflammation. Lower doses of corticosteroids provide an anti-inflammatory effect, while higher doses are immunosuppressive.
|
Creator: Daphnee Created On: June 06, 2023 at 16:00 Last Updated: June 06, 2023 at 16:00 |
PW144712 |
drug action
Ulobetasol Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:16 Last Updated: October 07, 2023 at 14:16 |
PW146902 |
drug action
Umbralisib Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 19:19 Last Updated: October 07, 2023 at 19:19 |
PW176159 |
Umbralisib Predicted Metabolism Pathway newHomo sapiens
Metabolites of Umbralisib are predicted with biotransformer.
|
Creator: Omolola Created On: November 29, 2023 at 14:24 Last Updated: November 29, 2023 at 14:24 |
PW145957 |
drug action
Umeclidinium Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 17:03 Last Updated: October 07, 2023 at 17:03 |
PW121986 |
disease
UMP Synthase Deficiency (Orotic Aciduria)Rattus norvegicus
Orotic aciduria, also known as UMP synthase deficiency, is an autosomal recessive disorder of pyrimidine metabolism caused by a defective uridine monophosphate synthetase (UMPS). UMPS is a multifunctional protein which carries out the functions of both orotate phosphoribosyltransferase (OPRT) and orotidine 5'-phosphate decarboxylase (ODC). UMPS catalyzes the conversion of orotic acid into uridine monophosphate (UMP) which is a nucleotide incorporated into ribonucleic acid (RNA). This disease is characterized by a very large accumulation of orotic acid in the urine, occasionally causing urinary obstruction. Symptoms of the disease include megaloblastic anemia as well as retarded growth and development.
|
Creator: Ana Marcu Created On: September 10, 2018 at 15:51 Last Updated: September 10, 2018 at 15:51 |